Mizuho analyst Uy Ear upgraded Relmada Therapeutics Inc (NASDAQ: RLMD) from Neutral to Outperform with a price target of $10.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE